Intravenous injection of Tspan8 antibody (CO029) has been shown to properly inhibit the drug resistance of non-CICs induced by CICs via exosomes [165], suggesting its use as a potential therapeutic target for PaCa. Here, TSPAN8 is linked to permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.